Actively Recruiting
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
Led by Industrial Farmacéutica Cantabria, S.A. · Updated on 2026-05-12
520
Participants Needed
13
Research Sites
106 weeks
Total Duration
On this page
Sponsors
I
Industrial Farmacéutica Cantabria, S.A.
Lead Sponsor
B
Bioskin GmbH
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn about oral minoxidil 1mg in the treatment of women with androgenetic alopecia, a type of hormone-imbalanced hair loss. The main questions to answer are to know about that minoxidil 1mg is as effective as minoxidil 2% topical solution (comparator product) and is more effective than placebo; and to ensure treatment with oral minoxidil is safe. Participants will be assigned randomly to receive one of the following treatment combinations: * the test product (oral minoxidil 1 mg, once/day) and the vehicle solution (vehicle means it looks like the comparator product, but it does not contain an active ingredient, 2 times/day), or * the placebo tablet (placebo means it looks like the test product, but it does not contain an active ingredient, once/day) and the comparator product (2% minoxidil solution, 2 times/day), or * the placebo tablet (once/day) and the vehicle solution (2 times/day). The clinical trial will take up to 36 weeks. During this time, patients will come to the clinical trial centre for 5 times for examinations and will be called by phone twice. At the visits, the following examinations will be performed: photos of the hair will be taken to determine hair density, assessment of changes in scalp hair growth, measurement of blood pressure, pulse, and body temperature, a physical examination, blood withdrawal to determine any abnormalities in the blood, urine sampling and analysis, performance of ECG, and evaluation of hypertrichosis (i.e., excessive hair growth over the body). Furthermore, patients will be asked daily whether they had experienced any side effects or took any new medications (or changed the dose of a known medication) or underwent any medical procedure. Also, women of childbearing potential must undergo pregnancy tests in blood and urine.
CONDITIONS
Official Title
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients aged 18 years or older with generally good health and no history of cardiovascular or other significant diseases
- Diagnosed with female androgenetic alopecia (FAGA) showing decreased hair density in the centroparietal scalp area (Sinclair Scale 2-4)
- Hair color that provides enough contrast with the scalp, confirmed by TrichoLab Virtual Tattoo technology at screening
- Signed informed consent indicating understanding of the trial procedures
- Negative pregnancy tests at screening and baseline for women of childbearing potential (WOCBP)
- WOCBP must be permanently sterile or use highly effective birth control throughout the trial and for at least 2 weeks after last treatment
- Stable use of gestagens with antiandrogen properties as contraceptives allowed if used for at least 6 months before baseline and continued during trial
- Willingness to keep the same hairstyle, hair color, and hair care routine during the trial
- Willingness to maintain consistent facial and body hair removal habits throughout the trial
- Ability and willingness to comply with scheduled visits, treatment plan, lab tests, and daily electronic diary recording using own device and internet
You will not qualify if you...
- Allergy or hypersensitivity to minoxidil or any product components
- Pregnancy or desire to become pregnant during the trial
- Breastfeeding or nursing women
- Diagnosed or untreated hypertension (blood pressure >150/95 mmHg) or history of cardiovascular disease
- Scalp dermatological disorders in the target area that may interfere with treatment or assessments, such as active moderate/severe seborrheic dermatitis, infections within past 3 months, active atopic dermatitis or psoriasis within past 6 months, other types of alopecia or pathological hair loss within past 3 months
- History of hair transplant surgery or hair extensions/weaving within past 6 months
- Abnormal laboratory or ECG results indicating illness
- Kidney function abnormalities (creatinine and eGFR above normal limits)
- Significant history of serious diseases that may interfere with trial objectives
- Use of topical scalp treatments affecting hair growth within specified timeframes before baseline (e.g., minoxidil, hormones, corticosteroids, laser, PRP)
- Use of certain systemic medications or therapies affecting hair growth within specified timeframes before baseline (e.g., vasodilators, 5 alpha reductase inhibitors, retinoids, beta blockers, antiandrogens, minoxidil, prostaglandins, biotin)
- Previous scalp radiation or chemotherapy treatments
- Participation in other investigational drug trials within 30 days or 5 half-lives before baseline
- History of drug or alcohol dependency
- Probable non-compliance or inability to understand the trial and provide informed consent
- Close relationship with the investigator or employment by sponsor or trial center
- Institutionalization due to legal or regulatory orders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
Fachklinik Bad Bentheim Klinisches Studienzentrum
Bad Bentheim, Germany
Actively Recruiting
2
CRC - Charité Universitätsmedizin Berlin Clinical Research Center for Hair and Skin Science
Berlin, Germany
Actively Recruiting
3
emovis by Futuremeds GmbH
Berlin, Germany
Actively Recruiting
4
Rosenpark Reasearch GmbH
Darmstadt, Germany
Not Yet Recruiting
5
Privatpraxis Dr. Hilton & Partner
Düsseldorf, Germany
Terminated
6
Klinik für Dermatologie, Venerologie und Allergologie - Universitätsmedizin Frankfurt
Frankfurt, Germany
Actively Recruiting
7
Dermaticum -Dr. med. Mario Bittar und Kollegen
Freiburg im Breisgau, Germany
Actively Recruiting
8
Eurofins bioskin - Research Center Dermatology
Hamburg, Germany
Actively Recruiting
9
Klinische Forschung Karlsruhe GmbH
Karlsruhe, Germany
Actively Recruiting
10
Siteworks - Prüfzentrum Lohne
Löhne, Germany
Active, Not Recruiting
11
Zentrale Studienkoordination für innovative Dermatologie (ZiD) Klinik für Hautkrankheiten Universitätsklinikum Münster (UKM)
Münster, Germany
Withdrawn
12
Haut-und Lasercentrum - Dr. Tanja Fischer und Kollegen
Potsdam, Germany
Actively Recruiting
13
TRIDERM Study Site Dermatological practice Dr. Leitz and colleagues
Stuttgart, Germany
Actively Recruiting
Research Team
A
Ana López-Ballesteros
CONTACT
J
Juan José Andrés Lencina
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here